

AD-A262 110



20030227070

(2)

AD \_\_\_\_\_

ACUTE T-2 INTOXICATION: PHYSIOLOGIC CONSEQUENCES  
AND NEW THERAPEUTIC APPROACHES

FINAL REPORT

GIORA Z. FEUERSTEIN

DECEMBER 30, 1992

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND  
Fort Detrick, Frederick, Maryland 21702-5012

Project Order No. 86PP6807

Uniformed Services University  
of the Health Sciences  
4301 Jones Bridge Road  
Bethesda, Maryland 20814

Approved for public release; distribution unlimited.

The findings in this report are not to be construed as an  
official Department of the Army position unless so designated  
by other authorized documents

DTIC  
ELECTE  
MAR 11 1993  
S C D

93-05152



808

88 10 000

| REPORT DOCUMENTATION PAGE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                             |                                                                         | Form Approved<br>OMB No 0704 0188       |  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------|--|
| <small>Public reporting burden for this report is estimated to be 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Project Director, Washington, DC 20503.</small> |                                                             |                                                                         |                                         |  |
| 1. AGENCY USE ONLY (Leave blank)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2. REPORT DATE<br>Dec. 30, 1992                             | 3. REPORT TYPE AND DATES COVERED<br>Final 1 Jan 86 - 31 Dec 88          |                                         |  |
| 4. TITLE AND SUBTITLE<br>Acute T-2 Intoxication: Physiologic Consequences and New Therapeutic Approaches                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                             | 5. FUNDING NUMBERS<br>86PP6807<br>62787A<br>3M162787A871 AA<br>DA309254 |                                         |  |
| 6. AUTHOR(S)<br>Giora Z. Feuerstein                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                             |                                                                         |                                         |  |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br>Uniformed Services University of the Health Sciences<br>4301 Jones Bridge Road<br>Bethesda, Maryland 20814                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                             | 8. PERFORMING ORGANIZATION<br>REPORT NUMBER                             |                                         |  |
| 9. SPONSORING MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research & Development Command<br>Fort Detrick<br>Frederick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                             | 10. SPONSORING MONITORING<br>AGENCY REPORT NUMBER                       |                                         |  |
| 11. SUPPLEMENTARY NOTES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                             |                                                                         |                                         |  |
| 12a. DISTRIBUTION AVAILABILITY STATEMENT<br>Approved for public release;<br>distribution unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                             | 12b. DISTRIBUTION CODE                                                  |                                         |  |
| 13. ABSTRACT (Maximum 200 words)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                             |                                                                         |                                         |  |
| 14. SUBJECT TERMS<br>RA 4; Mycotoxin; Physiology; Therapy;<br>Monoclonal antibody                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                             | 15. NUMBER OF PAGES                                                     |                                         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                             | 16. PRICE CODE                                                          |                                         |  |
| 17. SECURITY CLASSIFICATION<br>OF REPORT<br>Unclassified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 18. SECURITY CLASSIFICATION<br>OF THIS PAGE<br>Unclassified | 19. SECURITY CLASSIFICATION<br>OF ABSTRACT<br>Unclassified              | 20. LIMITATION OF ABSTRACT<br>Unlimited |  |

19 JAN 1993

## FINAL REPORT

Contract Effort: 86PP6807

Title: Acute T-2 intoxication: physiologic consequences and new therapeutic approaches

Objective: The objectives of this contracts were two: 1) to study the physiologic consequences of acute intoxication with T-2 mycotoxin; 2) to develop therapeutic modalities to reduce morbidity and mortality from severe T-2 toxin exposure.

### SPECIFIC AIMS

#### Specific Aim 1

To characterize the cardiorespiratory hematological and general autonomic responses to mild, moderate or severe exposure to T-2 mycotoxin.

These studies were conducted in rats and guinea pigs which were chronically instrumented to allow direct monitoring of cardiorespiratory variables. Some studies were also conducted in pithed rats to evaluate peripheral effects of T-2 toxin without modulatory effects of the central nervous system (baroreflexes, etc.). All studies were conducted in a dose-response manner. In the rat, T-2 toxin at (0.5-2.0 mg/kg, i.v.) produced hyperdynamic state marked by hypertension and tachycardia followed by hypotension and shock. Marked increases in total peripheral resistance underlied the hypertensive phase as cardiac output was reduced. In guinea pigs, T-2 toxin (0.5-2.0 mg/kg, i.v.) only hypotension and bradycardia were observed. All doses of T-2 toxin produced mortality; in rats, 0.5, 1.0 or 2.0 mg/kg resulted in 61, 24 and 0% survival, respectively. While, in guinea pigs, the same dosing regimen resulted in 72, 57 and 20% survival. Interestingly, in pithed rats, T-2 toxin failed to elicit the early hypertensive/tachycardic response, indicating a central mediated mechanism of this hyperdynamic state (these observations led to the studies on the central effects of T-2, vide supra). In rats, marked stimulation of the sympatho-adrenomedullary system was evidenced by elevated circulating levels of norepinephrine, epinephrine and dopamine.

Design For

CRA&I

TAB

Classification

By

Distribution /

Availability, Code

Dist

Avail and/or  
Special

A-1

Furthermore, significant neuroendocrine derangements were noted by elevated circulating levels of vasopressin and selected prostanoids (e.g., prostacyclin but not LTC<sub>4</sub> or TXA<sub>2</sub>).

The most prominent consequences to T-2 toxin administration in both guinea pigs and rats were severe acidosis, hypocarbia, without hypoxemia. In fact, hypoxemia was dose-dependent in both species. These metabolic changes were also observed in pithed rats suggesting peripheral organ toxication of aerobic metabolism. Additional interesting features of T-2 toxemia were: enhanced epinephrine release from spinal cord stimulated pithed rat and modest elevation of hematocrit. Taken together, these comprehensive studies in two species clearly indicated high toxicity of T-2 toxin and a broad, multi-organ/multisystem involvement. These studies were described in detail in *The Journal of Pharmacology and Experimental Therapeutics* 232:786-794, 1985.

### Specific Aim 2

To characterize in more detail the hemodynamic derangements monitored in the first study (vide supra), rats were chronically instrumented with Doppler flow probes which allow to follow selected organ blood flow and vascular resistance. In conscious rats, intravenous administration of T-2 toxin (1 mg/kg), resulted in reduced blood flow and increased vascular resistance in hindquarters, mesenteric and renal vascular beds. The reduction in hindquarter blood flow preceded the renal and mesenteric flows but, ultimately (30-60 min post-dosing), blood flows to all organs were severely compromised. Changes in systemic blood pressure was moderate, presumably due to the counteracting effect of the reduced cardiac output.

Since this study revealed renal hypoperfusion, a phenomenon known to result in activation of the renin-angiotensin system, the circulating levels of renin (as PRA) were monitored. Indeed, T-2 toxin (0.75 mg/kg, i.v.) resulted in marked increase in PRA, at the time of severe renal hypoperfusion only (>1 hr post T-2 dosing). Taken together, this study confirmed the previous report where marked increase in total peripheral resistance was noted and further extended this observation to selected somatic and splanchnic organs. The study also reported the activation of the third pressor system, renin-angiotensin, in addition to activation of the sympatho-adrenomedullary system and vasopressin release. Most importantly, the severe reduction in organ blood flow explained the marked metabolic (lactic) acidosis, typical to organ ischemia.

These experiments are described in detail in the publication *Toxicology and Applied Pharmacology* 83:438-444, 1986.

### Specific Aim 3

Evidence in support for central effects of T-2 toxin has been generated by both our own work (vide supra) as well as other reports published at the time of conducting our own research. First, we have followed the vasopressin response (marked release) and explored its content in the pituitary gland along with oxytocin, a peptide co-stored and released with vasopressin. Indeed, T-2 toxin (1 mg/kg, i.v.) depleted much of the vasopressin and oxytocin in the posterior pituitary gland; interestingly, the opioid peptide, leu-enkephalin, was also reduced while methionine-enkephaline content increased. Dynorphin content did not change. Thus, T-2 toxemia seems to produce a highly differentiated neuroendocrine response. These data were published in detail (*Science* 228:606-608, 1985).

Furthermore, we followed the eicosanoid lead described in Specific Aim 1, i.e., selective increase in plasma prostacyclin in T-2 toxemia. To this end, brain slices were studied *in vitro* (rat) following T-2 toxin dosing (0.75-2.0 mg/kg, i.v.) or *in vitro* exposure of brain slices to a wide range of T-2 toxin concentrations. *Ex vivo* assay of the eicosanoids in brain slices of *in vivo* dosing with T-2 toxin enhanced release of 6-keto-PGF<sub>1α</sub> (stable metabolite of PGI<sub>2</sub>) and TXB<sub>2</sub> (stable metabolite of TXA<sub>2</sub>) in cortical but not in the hypothalamus or nucleus tactus solitarius (NTS). PGE<sub>2</sub> showed time and dose related increments in both the cortex and hypothalamus but not NTS. *In vitro* incubation of cortical slices with T-2 toxin (10<sup>-9</sup>-10<sup>-3</sup>M) demonstrated a complex response: stimulation of PGE<sub>2</sub> and TXB<sub>2</sub> release from cortical slices at low (10<sup>-7</sup>M) concentration and inhibition at high (10<sup>-4</sup>M). These data elude to a direct effect of T-2 toxin on tissue phospholipase A<sub>2</sub> (activation) but also inhibitory effects on special eicosanoid metabolic pathways. These studies were published in detail in *Prostaglandins* 31:307-319, 1986.

In addition to neurochemical effects of T-2 toxemia, we have also studied behavioral and autonomic responses to T-2 toxin. Direct administration of T-2 toxin into the cerebroventricular (ICV) system of the rat produced cardiovascular responses at doses which had no such effect when given systemically. This, ICV T-2 toxin at 100 μg/kg, elicited pressor and tachycardic responses; a higher dose, 300 μg/kg, ICV, produced progressive and sustained hypertension and tachycardia compared to only transient effects upon systemic administration. Furthermore, at 300 mg/kg, ICV, only 50% of the rats survived at 24 hr, while the same dose given systemically did not result in any mortality by 72 hr post-dosing. These studies were

published in *Trichothecene Mycotoxins* Vol. 11:111-122, 1989, V. R. Beasley, ed., CRC Press.

#### Specific Aim 4

A major goal of our research on T-2 toxemia was the development of therapeutic approaches to this severe toxic agent.

##### A. Studies with PAF antagonist, BN52021

Our first approach to combat T-2 toxicity stemmed from studies with platelet-activating factor (PAF) antagonists in lipopolysaccharide (LPS) endotoxemia where various PAF antagonists have shown significant protection and reduced mortality from LPS-lethal toxemia. We, therefore, utilized a specific PAF-antagonist, BN52021, in our conscious rat model where an ED<sub>50</sub> dose of T-2 was given i.v. and the PAF antagonist administered at various time points before and/or post T-2 dosing. In three separate experiments, BN52021 significantly enhanced survival (3 day, final). The most significant study was that where BN52021 (15 mg/kg) given 3 hrs post T-2 dosing significantly (more than tripled) enhanced survival rate. BN52021 is now in Phase III clinical development for treatment of endotoxemia (gram negative) and is potentially of great value also for T-2 toxemia. This study was published in *Toxicology Letters* 38:271-274, 1987.

##### B. Studies with Dexamethasone

Glucocorticosteroids are known to protect animals against lethal doses of endotoxins, especially when given as prophylactic therapy. Glucocorticosteroids are also known to suppress the formation of eicosanoids, which were argued to play a role in the pathomechanisms of a variety of toxemias. Since we have found evidence in support of activation of eicosanoid synthesis also in T-2 toxemia, we have chosen to test the efficacy of dexamethasone, a potent, synthetic glucocorticosteroid in our rat T-2 toxemia model. Dexamethasone (2 mg/kg, i.v.) was given 1 hr post T-2 dosing; at 10 mg/kg, 1 and 24 hr post T-2 dosing; 1 mg/kg at 1, 24 and 48 hr post dosing or 10 mg/kg at 3 hr post T-2 toxin. The triple dosing (1 mg/kg, 1, 24 and 48 hr) resulted in remarkable increased survival (over 60% compared to 0% in controls); the other protocols also improved survival at various (but lesser) degrees. Interestingly, the dual cyclooxygenase/lipoxygenase inhibitor BW755c, failed to provide any consistent protection against

T-2 toxemia Dexamethasone also protected against T-2 toxin induced inhibition of PGE<sub>2</sub> synthesis in brain 24 hr post dosing.

This study was published in *Pharmaceutical Research* 4:527-530, 1987.

### C. Studies with monoclonal antibodies against T-2 toxin

In collaboration with Dr. K. Hunter, a monoclonal antibody (MAb) against T-2 toxin has been raised (mouse IgG1) and labeled 15H6. These MAbs were shown to induce net efflux of <sup>3</sup>H-T-2 toxin from poisoned human B-lymphoblastoid cells in vitro and restore protein synthesis. Administration of the MAb (250 mg/kg, i.v.) 30 min before infusion of lethal dose of endotoxin (1 mg/kg, i.v.) caused sequestration of the toxin in the plasma compartment. Administration of the MAb 35 min after the T-2 administration resulted in migration of T-2 toxin back into the plasma. These data (published in *The Journal of Pharmacology and Experimental Therapeutics* 255:1183-1187, 1990) demonstrate that monoclonal antibodies can be of therapeutic value against an intracellular toxin and, specifically, T-2 toxin.

The above studies prompted us to investigate the therapeutic capacity of 15H6 MAb in lethal T-2 toxemia. In our conscious rat T-2 toxemia model, where 1 mg/kg T-2 caused 100% mortality, 15H6 treated rats (250 mg/kg, i.v., 30 min after or 15 min after T-2 dosing) demonstrated 100% protection. When 15H6 was given 60 min post, T-2 still produced 45% protection.

Taken together, our studies with 15H6 MAb have resulted in a pioneering experience of a novel strategy to salvage cells/organs from actions of intracellular toxins and, in particular, successful use of this antibody as a tool for prophylactic and therapeutic utility (Study published in *J Clin Invest* 76:2134-2138, 1985).

### SUMMARY

Our research on T-2 toxemia has resulted in comprehensive evaluation of all major systems and, in particular, the cardiovascular, respiratory, autonomic and neuroendocrine. Our research has also led to identification of three different therapeutic modalities: PAF antagonists, dexamethasone and monoclonal antibodies (15H6). The latter strategy could well be further developed into human use by "humanizing" the 15H6 antibody through molecular engineering approaches. This research program was exciting, scientifically rewarding and of significant clinical potential.

On a final note, I maintain deep respect and gratitude to USMRDC/USAMRIID for sponsoring such research which clearly benefits both the military and civilian society.

PUBLICATIONS OF WORK DONE UNDER CONTRACT:

1. Feuerstein G, Goldstein DS, Ramwell PW, Zerbe RL, Lux WE Jr, Faden AI, Bayorh MA: Cardiorespiratory, sympathetic and biochemical responses to T-2 toxin in the guinea pig and rat. *J Pharmacol Exptl Ther* 232:786-794, 1985.
2. Zamir N, Zamir D, Eiden LE, Palkovits M, Brownstein MJ, Eskay RL, Weber E, Faden AI and Feuerstein G: Methionine and leucine enkephalin in rat neurohypophysis: different responses to osmotic stimuli and T<sub>2</sub> toxin. *Science* 228:606-608, 1985.
3. Feuerstein G, Powell JA, Knower AT, Hunter KW Jr: Monoclonal antibodies to T-2 toxin: in vitro neutralization of protein synthesis inhibition and protection of rats against lethal toxemia. *J Clin Invest* 76:2134-2138, 1985.
4. Siren A-L and Feuerstein G: Effect of T-2 toxin on regional blood flow and vascular resistance in the conscious rat. *Toxicol Appl Pharmacol* 83:438-444, 1985.
5. Shohami E and Feuerstein G: T-2 toxemia and brain prostaglandins. *Prostaglandins* 31:307-319, 1986.
6. Feuerstein G, Leader P, Siren A-L, Braquet P: Protective effect of a PAF-acether antagonist, BN52021, in trichothecene toxicosis. *Toxicol Lett* 38:271-274, 1987.
7. Shohami E, Wisotsky B, Kempinski O, Feuerstein G: Therapeutic effect of dexamethasone in T-2 toxicosis. *Pharmaceutical Res* 4:527-530, 1987.
8. Feuerstein G, Lorenzana RM, Beasley VR: Effects of trichothecene mycotoxins on the nervous system. In: *Trichothecene Mycotoxins*, Vol. 11, Beasley VR, ed., CRC Press, 1989, pp. 111-122.
9. Hunter KW Jr, Brimfield AA, Knower AT, Powell JA and Feuerstein G: Reversal of intracellular toxicity of the trichothecene mycotoxin T-2 with monoclonal antibody. *J Pharmacol Exptl Ther* 255:1183-1187, 1990.